title: Does desloratadine alter the serum levels of montelukast when administered in a fixed-dose combination?
abstract: OBJECTIVE
  The aim of this study was to investigate the serum levels of montelukast when administered alone or in combination with desloratadine.
  
  
  METHODS
  A prospective crossover study.
  
  
  METHODS
  Twenty-three healthy volunteers were investigated in two sessions. Volunteers were given 10 mg of montelukast orally with 250 mL water in the first session. The same subjects were given 10 mg of montelukast in fixed combination with 5 mg desloratadine 10 days after first session. Blood samples were collected 2, 3, and 4 hours after drug administration, and kept at -80°C after both applications. Plasma samples were analyzed for montelukast concentration.
  
  
  RESULTS
  Mean concentration values of both groups were not statistically different (P > .05), but the differences were statistically significant according to time (P < .05). Statistically significant difference was not found between the groups according to the area under curve on the basis of both marginal and cumulative values for all different time intervals (P > .05).
  
  
  CONCLUSIONS
  The absorption rate of montelukast was not altered when administered with desloratadine. This study suggested that desloratadine does not influence the bioavailability of montelukast, and their combination therapy can be used safely.
authors.affiliation: Medical Faculty, Department of Otorhinolaryngology, Osmangazi University, Eskisehir, Turkey.
authors.forename: Cemal
authors.initials: C
authors.lastname: Cingi
authors.forename: Sema Zer
authors.initials: SZ
authors.lastname: Toros
authors.forename: Iskender
authors.initials: I
authors.lastname: Ince
authors.forename: Cigdem Kalaycik
authors.initials: CK
authors.lastname: Ertugay
authors.forename: M Kezban
authors.initials: MK
authors.lastname: Gurbuz
authors.forename: Hamdi
authors.initials: H
authors.lastname: Cakli
authors.forename: Nagehan
authors.initials: N
authors.lastname: Erdogmus
authors.forename: Ercument
authors.initials: E
authors.lastname: Karasulu
authors.forename: Ercan
authors.initials: E
authors.lastname: Kaya
mesh_terms: D000085:Acetates / Q000008:administration & dosage* / Q000097:blood*; D000328:Adult; D001682:Biological Availability; D018592:Cross-Over Studies; D003521:Cyclopropanes; D004347:Drug Interactions; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage* / Q000097:blood*; D017336:Loratadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage* / Q000097:blood*; D013440:Sulfides; D055815:Young Adult
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D039563:Histamine H1 Antagonists, Non-Sedating; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D017336:Loratadine; C121345:desloratadine; C093875:montelukast
keywords: Desloratadine; allergy; bioavailability; drug interaction; fix molecules; montelukast